Onychomatricoma with Classic Features: Case Report and Review of the Literature

The document reports on the incidence of alopecia from endocrine therapies in cancer patients, finding that hair loss is a common but underreported side effect of such treatments. The systematic analysis included 35 clinical trials from 1966-2012, involving a total of 14,769 patients. Alopecia rates varied with different drugs: 0 to 9.4% for aromatase inhibitors (anastrozole, letrozole, exemestane), 9.5% for the LHRH agonist leuprolide, 0 to 8% for fulvestrant, 0.5 to 11% for megestrol, and 0 to 17% for tamoxifen. The cancers most commonly associated with alopecia were breast (74%) and prostate (5.7%). The study emphasizes the importance of recognizing alopecia as a quality of life issue for patients undergoing long-term endocrine therapy for cancer.